| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | HAE | Common Stock | Award | $0 | +24.7K | +79.18% | $0.00 | 56K | May 28, 2024 | Direct | F1, F2 |
| transaction | HAE | Common Stock | Tax liability | -$1.13M | -11.8K | -20.99% | $95.73 | 44.2K | May 28, 2024 | Direct | F2, F3 |
| transaction | HAE | Common Stock | Sale | -$782K | -8.9K | -20.11% | $87.86 | 35.4K | May 29, 2024 | Direct | F2, F4, F5 |
| transaction | HAE | Common Stock | Sale | -$363K | -4.09K | -11.58% | $88.57 | 31.3K | May 29, 2024 | Direct | F2, F4, F6 |
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
| Id | Content |
|---|---|
| F1 | Represents shares earned from a performance share unit ("PSU") award granted to the reporting person on May 18, 2021, based on the issuer's total shareholder return relative to that of the companies comprising the S&P MidCap 400 Index for the performance period from May 18, 2021 to May 17, 2024, as certified by the Compensation Committee of the Board of Directors on May 26, 2024. |
| F2 | This number includes unvested restricted stock units ("RSUs") previously reported. |
| F3 | Represents shares withheld for tax obligations in connection with the vesting of certain PSUs reported in Table I. |
| F4 | Transaction pursuant to an existing 10b5-1 trading plan dated December 13, 2023 (fully executed as of December 14, 2023). |
| F5 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.28 to $88.28, inclusive. The reporting person undertakes to provide to Haemonetics Corporation ("Haemonetics"), any security holder of Haemonetics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (5) and (6) to this Form 4. |
| F6 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.29 to $88.92, inclusive. |